603520.SHG Zhejiang Starry Pharm Co Ltd

Healthcare Pharmaceuticals Shanghai Stock Exchange
8.23 CNY
Close of Nov 4, 2026
7.64 14.37
Market cap
CNY 3.61B
P/E
164.6x
P/B
1.44x
ROE
2.4%
Dividend yield
4.05%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 603520.SHG undervalued?

Graham number

The Graham number of Zhejiang Starry Pharm Co Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zhejiang Starry Pharm Co Ltd fundamental analysis

No fundamental analysis for Zhejiang Starry Pharm Co Ltd yet.

Zhejiang Starry Pharm Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zhejiang Starry Pharm Co Ltd

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium,…

Full company profile